<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375943</url>
  </required_header>
  <id_info>
    <org_study_id>FedericoIIArcaAmd</org_study_id>
    <nct_id>NCT04375943</nct_id>
  </id_info>
  <brief_title>Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study</brief_title>
  <official_title>Clinical and Echocardiographic Management of Patients With Chronic Heart Failure and Type 2 Diabetes Mellitus: the SCODIAC Follow up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has been carried out to determine diagnostic and therapeutic pathways in a group of
      HF diabetic patients and to verify whether the use of innovative antidiabetic therapies could
      modify echocardiographic parameters and influence cardiological therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      406 patients affected with heart failure and Type 2 Diabetes Mellitus, referred to
      Cardiologists and Diabetologists of pertaining healthcare districts in Campania, and followed
      for at least one year between 2018 and 2019, were enrolled in this retrospective study and
      divided in Group A, composed of 136 HF diabetic patients with preserved Ejection Fraction
      (HF-pEF) (&gt;45%) and Group B, formed of 270 HF diabetic patients with reduced EF (HF-rEF)
      (≤45%). All patients had performed periodic clinical evaluations and an echocardiographic
      exam every 12 months. Anthropometric parameters, HF etiology, co-morbidities, complications
      and ongoing therapies were collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Cholesterol, LDL, HDL Triglycerides, Creatinine</measure>
    <time_frame>12 months</time_frame>
    <description>mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B-type natriuretic peptide (BNP)</measure>
    <time_frame>12 months</time_frame>
    <description>pmol/m</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 months</time_frame>
    <description>mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ejection Fraction</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular End-Diastolic Volume Index (LV-EDVi), Left Ventricular End-Systolic Volume Index (LV-ESVi), Left Atrial Volume Index (LAVi)</measure>
    <time_frame>12 months</time_frame>
    <description>ml/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>E velocity, A velocity,E' velocity</measure>
    <time_frame>12 months</time_frame>
    <description>m/sec</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">406</enrollment>
  <condition>Diabetes</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>diabetic HF-pEF patients</arm_group_label>
    <description>It is composed of 136 HF diabetic patients with preserved Ejection Fraction (HF-pEF) (&gt;45%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic HF-rEF patients</arm_group_label>
    <description>It is composed of 270 HF diabetic patients with reduced EF (HF-rEF) (≤45%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidiabetic</intervention_name>
    <description>Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy</description>
    <arm_group_label>diabetic HF-pEF patients</arm_group_label>
    <arm_group_label>diabetic HF-rEF patients</arm_group_label>
    <other_name>SGLT2 inhibitors, gliflozins, echocardiography.</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 406 patient with HF and T2DM, referred to ARCA Cardiologists from 17 healthcare
        districts in Campania and to AMD Physicians from 8 Antidiabetic Centers and followed for at
        least one year between 2018 and 2019, were enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age at least 65 years

          -  presence of chronic HF, defined as a stable clinical syndrome with typical symptoms
             and signs and echocardiographic evidence of cardiac involvement

          -  New York Heart Association (NYHA) class II-III

          -  diagnosis of T2DM from at least 2 years

        Exclusion Criteria:

          -  cardiac surgery performed during the last year

          -  age less than 65 years

          -  significant valvulopathies

          -  malignant neoplasms

          -  advanced chronic kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ugo Oliviero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federico II University</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Oliviero Ugo</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>heart failure</keyword>
  <keyword>ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

